Vedolizumab-Induced De Novo Extraintestinal Manifestations.
Background: Vedolizumab is an α4β7 integrin antagonist with gut-specific effects on lymphocyte and monocyte trafficking. Although the treatment is beneficial for inflammatory bowel disease (IBD), the effects of vedolizumab on extraintestinal manifestations (EIMs) have not been well described. The gu...
| Publicado en: | Gastroenterology & Hepatology Vol. 16; no. 2; pp. 74 - 81 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Gastro-Hep Communications, Inc
Feb2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |